ES2369535T3 - Uso de alquilfosfocolinas en combinación con medicamentos antitumorales. - Google Patents
Uso de alquilfosfocolinas en combinación con medicamentos antitumorales. Download PDFInfo
- Publication number
- ES2369535T3 ES2369535T3 ES03766336T ES03766336T ES2369535T3 ES 2369535 T3 ES2369535 T3 ES 2369535T3 ES 03766336 T ES03766336 T ES 03766336T ES 03766336 T ES03766336 T ES 03766336T ES 2369535 T3 ES2369535 T3 ES 2369535T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- amino
- branched
- independently
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 title description 8
- -1 alkyl phosphocholines Chemical class 0.000 claims abstract description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 4
- 230000000340 anti-metabolite Effects 0.000 claims abstract description 3
- 229940100197 antimetabolite Drugs 0.000 claims abstract description 3
- 239000002256 antimetabolite Substances 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 6
- 201000008275 breast carcinoma Diseases 0.000 description 6
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- 229960005536 Alkyl-lysophospholipid Drugs 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009396 radiation induced apoptosis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39961502P | 2002-07-30 | 2002-07-30 | |
| US399615P | 2002-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2369535T3 true ES2369535T3 (es) | 2011-12-01 |
Family
ID=31495746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03766336T Expired - Lifetime ES2369535T3 (es) | 2002-07-30 | 2003-07-29 | Uso de alquilfosfocolinas en combinación con medicamentos antitumorales. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8389497B2 (OSRAM) |
| EP (2) | EP1545553B1 (OSRAM) |
| JP (1) | JP2005535688A (OSRAM) |
| KR (3) | KR20110102485A (OSRAM) |
| CN (1) | CN1302780C (OSRAM) |
| AR (1) | AR040717A1 (OSRAM) |
| AT (1) | ATE516036T1 (OSRAM) |
| AU (2) | AU2003253350B2 (OSRAM) |
| BR (1) | BR0313048A (OSRAM) |
| CA (1) | CA2493023C (OSRAM) |
| CY (1) | CY1111902T1 (OSRAM) |
| DK (1) | DK1545553T3 (OSRAM) |
| ES (1) | ES2369535T3 (OSRAM) |
| HR (1) | HRP20050184B1 (OSRAM) |
| IL (1) | IL166329A (OSRAM) |
| MX (1) | MXPA05001203A (OSRAM) |
| NO (1) | NO335196B1 (OSRAM) |
| NZ (1) | NZ538428A (OSRAM) |
| PL (1) | PL375493A1 (OSRAM) |
| PT (1) | PT1545553E (OSRAM) |
| RU (1) | RU2005105693A (OSRAM) |
| SI (1) | SI1545553T1 (OSRAM) |
| TW (1) | TWI332007B (OSRAM) |
| UA (1) | UA82322C2 (OSRAM) |
| WO (1) | WO2004012744A1 (OSRAM) |
| ZA (1) | ZA200500453B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ538428A (en) | 2002-07-30 | 2006-09-29 | Zentaris Gmbh | Use of alkylphosphocholines in combination with antitumor medicaments |
| US8383605B2 (en) | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| DE10324911B4 (de) | 2003-05-30 | 2005-08-18 | Siemens Ag | Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen |
| WO2006081452A2 (en) * | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
| KR101378005B1 (ko) | 2005-12-19 | 2014-03-27 | 아에테르나 젠타리스 게엠베하 | 세포독성이 감소된 알킬 인지질 유도체 및 이의 용도 |
| US20070167408A1 (en) * | 2005-12-19 | 2007-07-19 | Zentaris Gmbh | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| EP1800684A1 (en) * | 2005-12-20 | 2007-06-27 | Zentaris GmbH | Novel alkyl phospholipid derivatives and uses thereof |
| US8703179B2 (en) | 2006-05-11 | 2014-04-22 | Kimberly-Clark Worldwide, Inc. | Mucosal formulation |
| KR20100092424A (ko) * | 2007-07-30 | 2010-08-20 | 아디아 바이오사이언스즈 인크. | 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법 |
| AU2009324464B2 (en) * | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CA2794513A1 (en) | 2010-03-31 | 2011-10-06 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59205998D1 (de) * | 1991-07-04 | 1996-05-23 | Asta Medica Ag | Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung |
| US5942639A (en) * | 1991-07-04 | 1999-08-24 | Asta Medica Aktiengesellschaft | Process for the preparation of alkylphosphocholines and the production thereof in pure form |
| US6172050B1 (en) * | 1992-07-11 | 2001-01-09 | Asta Medica Aktiengesellschaft | Phospholipid derivatives |
| JP3079993B2 (ja) * | 1996-03-27 | 2000-08-21 | 日本電気株式会社 | 真空マイクロデバイスおよびその製造方法 |
| DE19650778C2 (de) * | 1996-12-06 | 2001-01-04 | Asta Medica Ag | Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie |
| SK284839B6 (sk) | 1998-01-22 | 2005-12-01 | Zentaris Gmbh | Použitie miltefozínu na výrobu lieku a farmaceutická kombinácia na liečenie leishmanózy |
| EP1135193B1 (de) * | 1998-12-04 | 2002-10-30 | Max-Delbrück-Centrum Für Molekulare Medizin | Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten |
| JP2002532553A (ja) * | 1998-12-21 | 2002-10-02 | インケイサ．ソシエダ アノニマ | 有害な胃腸副作用を引き起こさない有力な抗炎症剤としてのエーテルリゾリン脂質の使用 |
| LT3351246T (lt) * | 2001-02-19 | 2019-07-10 | Novartis Pharma Ag | Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui |
| DE60234577D1 (de) * | 2001-03-23 | 2010-01-14 | Shire Canada Inc | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält |
| WO2003005522A1 (es) | 2001-07-04 | 2003-01-16 | Acuna Arturo | Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica. |
| DK1461083T3 (da) * | 2002-01-02 | 2006-07-10 | Nerviano Medical Sciences Srl | Kombineret terapi mod tumorer omfattende substitueret acryloyl distamycinderivater og proteinkinase- (serin/threoninkinase) inhibitorer |
| NZ538428A (en) | 2002-07-30 | 2006-09-29 | Zentaris Gmbh | Use of alkylphosphocholines in combination with antitumor medicaments |
| WO2005000318A2 (en) * | 2003-06-23 | 2005-01-06 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| WO2006081452A2 (en) | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
| US20070167408A1 (en) * | 2005-12-19 | 2007-07-19 | Zentaris Gmbh | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| CA2794513A1 (en) | 2010-03-31 | 2011-10-06 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
-
2003
- 2003-07-29 NZ NZ538428A patent/NZ538428A/en not_active IP Right Cessation
- 2003-07-29 WO PCT/EP2003/008346 patent/WO2004012744A1/de not_active Ceased
- 2003-07-29 HR HRP20050184AA patent/HRP20050184B1/hr not_active IP Right Cessation
- 2003-07-29 TW TW092120705A patent/TWI332007B/zh not_active IP Right Cessation
- 2003-07-29 EP EP03766336A patent/EP1545553B1/de not_active Expired - Lifetime
- 2003-07-29 KR KR1020117017914A patent/KR20110102485A/ko not_active Ceased
- 2003-07-29 DK DK03766336.6T patent/DK1545553T3/da active
- 2003-07-29 AT AT03766336T patent/ATE516036T1/de active
- 2003-07-29 ES ES03766336T patent/ES2369535T3/es not_active Expired - Lifetime
- 2003-07-29 UA UAA200500510A patent/UA82322C2/uk unknown
- 2003-07-29 PL PL03375493A patent/PL375493A1/xx unknown
- 2003-07-29 AR AR20030102710A patent/AR040717A1/es unknown
- 2003-07-29 BR BR0313048-7A patent/BR0313048A/pt not_active IP Right Cessation
- 2003-07-29 CA CA2493023A patent/CA2493023C/en not_active Expired - Lifetime
- 2003-07-29 SI SI200332027T patent/SI1545553T1/sl unknown
- 2003-07-29 PT PT03766336T patent/PT1545553E/pt unknown
- 2003-07-29 KR KR1020057001510A patent/KR101066804B1/ko not_active Expired - Lifetime
- 2003-07-29 EP EP10010451A patent/EP2301551A1/de not_active Withdrawn
- 2003-07-29 JP JP2004525354A patent/JP2005535688A/ja active Pending
- 2003-07-29 CN CNB038181010A patent/CN1302780C/zh not_active Expired - Fee Related
- 2003-07-29 KR KR1020127034433A patent/KR20130016413A/ko not_active Ceased
- 2003-07-29 RU RU2005105693/15A patent/RU2005105693A/ru unknown
- 2003-07-29 AU AU2003253350A patent/AU2003253350B2/en not_active Ceased
- 2003-07-29 MX MXPA05001203A patent/MXPA05001203A/es active IP Right Grant
- 2003-07-30 US US10/632,187 patent/US8389497B2/en not_active Expired - Fee Related
-
2005
- 2005-01-17 IL IL166329A patent/IL166329A/en not_active IP Right Cessation
- 2005-01-18 ZA ZA2005/00453A patent/ZA200500453B/en unknown
- 2005-02-25 NO NO20051040A patent/NO335196B1/no not_active IP Right Cessation
-
2008
- 2008-07-10 AU AU2008203060A patent/AU2008203060B2/en not_active Ceased
-
2010
- 2010-03-31 US US12/751,608 patent/US8507710B2/en not_active Expired - Fee Related
- 2010-03-31 US US12/751,454 patent/US8551977B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 CY CY20111100944T patent/CY1111902T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008203060B2 (en) | Use of alkyl phosphocholines in combination with antitumor medicaments | |
| ES2621857T3 (es) | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 | |
| ES2222466T3 (es) | Uso de flavanolignanos para la preparacion de medicamentos con actividad antiproliferativa en utero, ovario y mama. | |
| ES2367028T3 (es) | Composiciones sinérgicas con fk-228. | |
| ES2545340T3 (es) | Terapia de la combinación para el tratamiento de enfermedades proliferativas | |
| ES2746105T3 (es) | Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer | |
| ES2727686T3 (es) | Tratamiento de enfermedades que implican mucina | |
| US20110028421A1 (en) | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals | |
| ES2743701T3 (es) | Conjugados de ligando-fármaco del receptor sigma-2 como compuestos antitumorales, métodos de síntesis y usos de los mismos | |
| ES2390801T3 (es) | Procedimiento para el tratamiento de la neoplasia con una combinación de agentes quimioterápicos y radiación | |
| ES2184496T3 (es) | Empleo de determinados acidos bifosfonicos y sus derivados para la fabricacion de farmacos para la prevencion y el tratamiento de enfermedades autoinmunes y alergias. | |
| AU2011204918B2 (en) | Use of alkylphosphocholines in combination with antitumor medicaments | |
| CA2436332A1 (en) | Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals | |
| WO2011046901A2 (en) | Broad spectrum antiviral and methods of use | |
| PT2404608E (pt) | Derivado de colestanol para utilização combinada |